Chief Medical Officer · Avalo Therapeutics, Inc. · Common Stock
Side
SELL
Value
$412K
Shares
25.5K
Price
$16.15
Executed
Mar 16, 2026
Disclosed
Mar 18, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Mar 16 executedMar 18, 2026 disclosed
AVTX · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Doyle Mittie filed this Form 4 reporting a open-market sale of AVTX on Mar 16, 2026. It became public on Mar 18, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Medical Officer
Doyle Mittiecik:0001918845
Issuer
Avalo Therapeutics, Inc.cik:0001534120
Revision history · 0
No field has changed since this record was first ingested.
